-
JTW, Coptisine, and DHEA-Driven PCOS Mechanisms
2026-09-20
A 2025 Phytomedicine study identifies SIRT1 ubiquitination and mitochondrial cholesterol import as a mechanistic link between Jiao-tai-wan, coptisine, and improved PCOS phenotypes. Its combined rat, primary theca-cell, imaging, proteomic, and target-engagement strategy provides a framework for studying steroidogenic dysfunction while clarifying that DHEA served as a disease-modeling agent rather than the tested therapy.
-
GANT61: A GLI Inhibitor for Mechanistic Assays
2026-09-19
GANT61 is a GLI inhibitor for dissecting Hedgehog transcriptional control, tumor growth suppression, and immune-evasion biology. This guide translates GLI2–WNT–prostaglandin findings into practical assay decisions while distinguishing established evidence from experimental extensions.
-
FGF4–FGFR1 Signaling in Diabetic Kidney Disease
2026-09-19
This Nature Communications study identifies podocyte-secreted FGF4 as an endogenous protector of glomerular integrity in diabetic kidney disease. Genetic loss-of-function, recombinant FGF4 treatment, and human podocyte experiments connect FGF4–FGFR1 signaling with AMPK–FOXO1 activation, reduced oxidative stress, lower apoptosis, and improved renal function in male diabetic mice.
-
MK-1775: Reading Wee1 Inhibitor Responses
2026-09-18
MK-1775 is a Wee1 kinase inhibitor whose effects can be misread when growth inhibition and cell death are treated as the same endpoint. This article presents a phenotype-aware framework for interpreting checkpoint abrogation, DNA damage response inhibition, and chemosensitization experiments.
-
DHEA Workflows for Neuroprotection and Ovarian Research
2026-09-18
Build reproducible DHEA experiments across neural survival, ovarian biology, and DHEA-induced PCOS models. This practical guide connects dosing, solvent handling, microbiome-aware study design, and troubleshooting to help distinguish direct steroid effects from exposure-related pathology.
-
HDAC Inhibition Reverses EBV-Driven NPC Plasticity
2026-09-17
The reference study identifies an epigenetic mechanism by which EBV protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma. It further shows that HDAC inhibition can restore CEBPA expression and partially reverse this state in cellular and xenograft models, supporting differentiation therapy as a strategy for poorly differentiated solid tumors.
-
Pheromone-Driven Neurodegeneration in C. elegans
2026-09-17
Peng et al. show that early exposure to C. elegans pheromones can reprogram neurodevelopment and accelerate neurodegeneration later in life. The study connects combinatorial chemosensory signaling through ASK, ASI, and AIA interneurons with insulin-like signaling and reduced neuronal autophagy, offering a mechanistic framework for studying environmental effects on proteostasis.
-
Z-YVAD-FMK: Caspase-1 Inhibitor Workflow
2026-09-16
Build cleaner inflammasome, pyroptosis, and apoptosis experiments with a cell-permeable, irreversible caspase-1 inhibitor. This workflow combines practical dosing and handling guidance with assay choices informed by new evidence on chicken gasdermin cleavage.
-
Moxifloxacin Workflows for Antibiotic Toxicity
2026-09-15
Build reproducible Moxifloxacin assays that connect DNA gyrase inhibition with cellular viability, retinal ganglion cell responses, and acute metabolic endpoints. This guide combines practical dose-response design, mechanistic controls, and troubleshooting for antibiotic toxicity research.
-
S Tag Peptide: Practical Fusion-Tag Workflow
2026-09-15
S Tag Peptide is a compact, highly soluble fusion tag for recombinant protein detection, antibody-based capture, and protein solubility improvement. This guide covers construct design, aqueous handling, QC, and troubleshooting while clarifying that the peptide is not a standalone ribonuclease reagent and is unsuitable for ethanol-based protocols.
-
Nintedanib in ATRX-Deficient Glioma Research
2026-09-14
Learn how Nintedanib (BIBF 1120) can support genotype-aware glioma assays, RTK/PDGFR inhibitor screening, and combination studies with temozolomide. The workflow emphasizes solubility control, ATRX-stratified comparisons, mechanistic readouts, and practical troubleshooting.
-
Praeruptorin A: Applied Research Workflows
2026-09-14
Praeruptorin A connects inflammation, ferroptosis, cardiomyopathy, and cancer-invasion assays through experimentally testable pathways rather than a single endpoint. This workflow translates its STAT-1/3, DMT1, ERK1/2, and MMP1 biology into practical dosing, controls, troubleshooting, and translational decision points.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-13
The 3X (DYKDDDDK) Peptide supports competitive elution, sensitive FLAG-fusion detection, and structurally informed protein workflows. This guide connects practical purification and assay decisions with lessons from a recent cryo-EM study of human PSS2.
-
GLI2, WNT, and Prostaglandins in Immunotherapy Resistance
2026-09-12
DeVito et al. identify GLI2 as a mechanistic coordinator linking mesenchymal transformation to WNT ligand production, prostaglandin signaling, and an immunosuppressive tumor microenvironment. The findings connect GLI2 activity with myeloid-derived suppressor cell recruitment, impaired cytotoxic lymphocyte function, and primary or adaptive resistance to anti-PD-1 therapy, providing a rationale for pathway-informed combination studies.
-
Atropo-Enantioselective Suzuki Synthesis: Rhazinilam Analog
2026-09-12
Herrbach and co-workers reported the first application of an asymmetric Suzuki cross-coupling to a biologically relevant axially chiral biaryl target. Screening and optimization of chiral phosphine ligands, particularly binaphthyl ligand 7a, furnished a nonbridged rhazinilam analogue precursor with up to 40% enantiomeric excess, establishing a catalytic route to the biologically relevant atropisomer.